Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?

Drug Safety

Volumn 32, Issue 8, 2009, Pages 625-636

  Hoet, Peter ^a,b   Legiest, Barbara ^a   Geys, Jorina ^a   Nemery, Benoit ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Laboratorium Voor Longtoxicologie   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; CHITOSAN; INSULIN; IRON OXIDE; LIPOSOME; NANOMATERIAL; NANOPARTICLE; SILICON DIOXIDE; TITANIUM DIOXIDE;

ATHEROSCLEROSIS; CARCINOGENICITY; CLINICAL ASSESSMENT; DRUG DELIVERY SYSTEM; EMULSION; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PARTICULATE MATTER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOSIS;

ANIMALS; ENVIRONMENTAL HEALTH; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NANOTECHNOLOGY; RISK ASSESSMENT; TOXICITY TESTS;

EID: 67650439354     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-200932080-00002     Document Type: Review

References (111)

1. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113 (7): 823-39
2. Maynard AD, Aitken RJ, Butz T, et al. Safe handling of nanotechnology. Nature 2006; 444 (7117): 267-9
3. The Royal Society & The Royal Academy of Engineering. Nanoscience and nanotechnologies: opportunities and uncertainties. Summary and recommendations [online]. Available from URL: http://www.nanotec.org.uk/final Report.htm [Accessed 2009 May 29]
4. Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol 2007; 18 (1): 26-30
5. Leroueil PR, Hong S, Mecke A, et al. Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? Acc Chem Res 2007; 40 (5): 335-42
6. Donaldson K, Seaton A. The Janus faces of nanoparticles. J Nanosci Nanotechnol 2007; 7 (12): 4607-11
7. Warheit DB, Borm PJ, Hennes C, et al. Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop. Inhal Toxicol 2007; 19 (8): 631-43
8. Medina C, Santos-Martinez MJ, Radomski A, et al. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007; 150 (5): 552-8
9. Sarker DK. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv 2005; 2 (4): 297-310
10. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004; 100 (1): 5-28
11. Cherian AK, Rana AC, Jain SK. Self-assembled carbohydratestabilized ceramic nanoparticles for the parenteral delivery of insulin. Drug Dev Ind Pharm 2000; 26 (4): 459-63
12. Yamamoto A, Honma R, Sumita M, et al. Cytotoxicity evaluation of ceramic particles of different sizes and shapes. J Biomed Mater Res A 2004; 68 (2): 244-56
13. Gupta AK, Naregalkar RR, Vaidya VD, et al. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomed 2007; 2 (1): 23-39
14. Weng J, Ren J. Luminescent quantum dots: a very attractive and promising tool in biomedicine. Curr Med Chem 2006; 13 (8): 897-909
15. Hirsch LR, Gobin AM, Lowery AR, et al. Metal nanoshells. Ann Biomed Eng 2006; 34 (1): 15-22
16. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008; 41 (1): 60-8
17. Lam CW, James JT, McCluskey R, et al. A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit Rev Toxicol 2006; 36 (3): 189-217
18. Murakami T, Tsuchida K. Recent advances in inorganic nanoparticle-based drug delivery systems. Mini Rev Med Chem 2008; 8 (2): 175-83
19. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006; 5 (4): 567-83
20. ICH. Note for guidance on preclinical safety evaluation of biotechnology-derived pharmaceuticals. ICH topic: preclinical safety evaluation of biotechnology-derived pharmaceuticals. London: EMEA, 1998; S6: 1-10
21. Fabian E, Landsiedel R, Ma-Hock L, et al. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch Toxicol 2008; 82 (3): 151-7
22. Worle-Knirsch JM, Pulskamp K, Krug HF. Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett 2006; 6 (6): 1261-8
23. Pulskamp K, Diabaté S, Krug HF. Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants. Toxicol Lett 2007; 1 (4): 293-9
24. Cui D, Tian F, Ozkan CS, et al. Effect of single wall carbon nanotubes on human HEK293 cells. Toxicol Lett 2005; 155: 73-85
25. Murr LE, Garza KM, Soto KF, et al. Cytotoxicity assessment of some carbon nanotubes and related carbon nanoparticle aggregates and the implications for anthropogenic carbon nanotube aggregates in the environment. Int J Environ Res Public Health 2005; 2 (1): 31-42
26. Soto KF, Carrasco A, Powell TG, et al. Comparative in vitro cytotoxicity assessment of some manufactured nanoparticulate materials characterized by transmission electron microscopy. J Nanopart Res 2005; 7: 145-69
27. Soto K, Garza KM, Murr LE. Cytotoxic effects of aggregated nanomaterials. Acta Biomater 2007; 3 (3): 351-8
28. Sayes CM, Wahi R, Kurian PA, et al. Correlating nanoscale titania structure with toxicity: a cytotoxicity and inflammatory response study with human dermal fibroblasts and human lung epithelial cells. Toxicol Sci 2006; 92 (1): 174-85
29. Zhang LW, Zeng L, Barron AR, et al. Biological interactions of functionalized single-wall carbon nanotubes in human epidermal keratinocytes. Int J Toxicol 2007; 26 (2): 103-13
30. Dutta D, Sundaram SK, Teeguarden JG, et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol Sci 2007; 100 (1): 303-15
31. Schimmelpfeng J, Drosselmeyer E, Hofheinz V, et al. Influence of surfactant components and exposure geometry on the effects of quartz and asbestos on alveolar macrophages. Environ Health Perspect 1992; 97: 225-31
32. Gao N, Keane MJ, Ong T, et al. Effects of phospholipid surfactant on apoptosis induction by respirable quartz and kaolin in NR8383 rat pulmonary macrophages. Toxicol Appl Pharmacol 2001; 175 (3): 217-25
33. Wallace WE, Keane MJ, Murray DK, et al. Phospholipid lung surfactant and nanoparticle surface toxicity: lessons from diesel soots and silicate dusts. J Nanopart Res 2007; 9: 23-38
34. Monteiro-Riviere NA, Nemanich RJ, Inman AO, et al. Multi-walled carbon nanotube interactions with human epidermal keratinocytes. Toxicol Lett 2005; 155: 377-84
35. Davoren M, Herzog E, Casey A, et al. In vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells. Toxicol In Vitro 2007; 21: 438-48
36. Wick P, Manser P, Limbach LK, et al. The degree and kind of agglomeration affect carbon nanotube cytotoxicity. Toxicol Lett 2007; 168 (2): 121-31
37. Smart SK, Cassady AI, Lu GQ, et al. The biocompatibility of carbon nanotubes. Carbon 2006; 44: 1034-47
38. Murdock RC, Braydich-Stolle L, Schrand AM, et al. Characterization of nanomaterial dispersion in solution prior to in vitro exposure using dynamic light scattering technique. Toxicol Sci 2007; 101 (2): 239-53
39. Monteiro-Riviere NA, Inman AO. Challenges for assessing carbon nanomaterial toxicity to the skin. Carbon 2006; 44: 1070-8
40. Hurt RH, Monthioux M, Kane A. Toxicology of carbon nanomaterials: status, trends, and perspectives on the special issue. Carbon 2006; 44: 1028-33
41. Hoet PH, Bruske-Hohlfeld I, Salata OV. Nanoparticles: known and unknown health risks. J Nanobiotechnol 2004; 2 (1): 12
42. Oberdörster G, Ferin J, Lehnert BE. Correlation between particle size, in vivo particle persistence, and lung injury. Environ Health Perspect 1994; 102 Suppl. 5: 173-9
43. Nemmar A, Hoet PH, Vanquickenborne B, et al. Passage of inhaled particles into the blood circulation in humans. Circulation 2002; 105 (4): 411-4
44. Nemmar A, Vanbilloen H, Hoylaerts MF, et al. Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. Am J Respir Crit Care Med 2001; 164 (9): 1665-8
45. Kreyling WG, Semmler M, Erbe F, et al. Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health A 2002; 65 (20): 1513-30
46. Rothen-Rutishauser B, Muhlfeld C, Blank F, et al. Translocation of particles and inflammatory responses after exposure to fine particles and nanoparticles in an epithelial airway model. Part Fibre Toxicol 2007; 4: 9
47. Muhlfeld C, Mayhew TM, Gehr P, et al. A novel quantitative method for analyzing the distributions of nanoparticles between different tissue and intracellular compartments. J Aerosol Med 2007; 20 (4): 395-407
48. Kling J. Inhaled insulin's last gasp? Nat Biotechnol 2008; 26 (5): 479-80
49. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev 2002; 54 Suppl. 1: S77-98
50. Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol Sci 2006; 91 (1): 159-65
51. Jani P, Halbert GW, Langridge J, et al. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 1990; 42 (12): 821-6
52. Yamago S, Tokuyama H, Nakamura E, et al. In vivo biological behavior of a water-miscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity. Chem Biol 1995; 2 (6): 385-9
53. Qu X, Khutoryanskiy VV, Stewart A, et al. Carbohydrateased micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. Biomacromolecules 2006; 7 (12): 3452-9
54. Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Respir Crit Care Med 2002; 166 (9): 1240-7
55. Takenaka S, Karg E, Roth C, et al. Pulmonary and systemic distribution of inhaled ultrafine silver particles in rats. Environ Health Perspect 2001; 109 Suppl. 4: 547-51
56. Nigavekar SS, Sung LY, Llanes M, et al. 3H Dendrimer nanoparticle organ/tumor distribution. Pharm Res 2004; 21 (3): 476-83
57. Sayes CM, Liang F, Hudson JL, et al. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett 2006; 161 (2): 135-42
58. 2 particles: differential responses related to surface properties. Toxicology 2007; 230 (1): 90-104
59. 2 particle formulations: impact of surface treatments on particle toxicity. Toxicol Sci 2005; 88 (2): 514-24
60. Lomer MC, Hutchinson C, Volkert S, et al. Dietary sources of inorganic microparticles and their intake in healthy subjects and patients with Crohn's disease. Br J Nutr 2004; 92 (6): 947-55
61. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004; 12 (2): 65-70
62. ICH. Note for guidance on the genotoxicity testing and datanterpretation for pharmaceuticals intended for human use. ICH topic: preclinical safety evaluation of biotechnologyderived pharmaceuticals. London: EMEA, 2008; S2: 1-28
63. Schins RP, Knaapen AM. Genotoxicity of poorly soluble particles. Inhal Toxicol 2007; 19 Suppl. 1: 189-98
64. Singh N, Manshian B, Jenkins GJ, et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials. Epub 2009 May 6
65. Choi AO, Brown SE, Szyf M, et al. Quantum dot-induced epigenetic and genotoxic changes in human breast cancer cells. J Mol Med 2008; 86 (3): 291-302
66. Baccarelli A, Wright RO, Bollati V, et al. Rapid DNA methylation changes after exposure to traffic particles. Am J Respir Crit Care Med 2009; 179 (7): 572-8
67. Donaldson K, Stone V. Current hypotheses on the mechanisms of toxicity of ultrafine particles. Ann Ist Super Sanita 2003; 39 (3): 405-10
68. Nel A, Xia T, Madler L, et al. Toxic potential of materials at the nanolevel. Science 2006; 311 (5761): 622-7
69. Poland CA, Duffin R, Kinloch I, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nano 2008; 3 (7): 423-8
70. Muller J, Decordier I, Hoet PH, et al. Clastogenic and an- eugenic effects of multi-wall carbon nanotubes in epithelial cells. Carcinogenesis 2008; 29 (2): 427-33
71. Semmler-Behnke M, Kreyling WG, Lipka J, et al. Biodistribution of 1.4- and 18-nm gold particles in rats. Small 2008; 4 (12): 2108-11
72. Takenaka S, Karg E, Kreyling WG, et al. Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal Toxicol 2006; 18 (10): 733-40
73. Dumortier H, Lacotte S, Pastorin G, et al. Functionalizedcarbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett 2006; 6 (7): 1522-8
74. Monteiller C, Tran L, MacNee W, et al. The proinflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area. Occup Environ Med 2007; 64 (9): 609-15
75. 2: role of the specific surface area and of surface methylation of the particles. Toxicol Appl Pharmacol 2007; 222 (2): 141-51
76. Gheshlaghi ZN, Riazi GH, Ahmadian S, et al. Toxicity and interaction of titanium dioxide nanoparticles with microtubule protein. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 777-82
77. Lipski AM, Pino CJ, Haselton FR, et al. The effect of silica nanoparticle-modified surfaces on cell morphology, cytoskeletal organization and function. Biomaterials 2008; 29: 3836-46
78. Kaiser JP, Wick P, Manser P, et al. Single walled carbon nanotubes (SWCNT) affect cell physiology and cell architecture. J Mater Sci Mater Med 2008; 19: 1523-7
79. Putman E, van der Laan JW, van LH. Assessing immuno toxicity: guidelines. Fundam Clin Pharmacol 2003; 17 (5): 615-26
80. Putman E, van der Laan JW, van Loveren H. Assessing immunotoxicity: guidelines. Fundam Clin Pharmacol 2003; 17: 615-26
81. Izhaky D, Pecht I. What else can the immune system recognize? Proc Natl Acad Sci U S A 1998; 95 (20): 11509-10
82. Mitchell LA, Gao J, Wal RV, et al. Pulmonary and systemic immune response to inhaled multiwalled carbon nanotubes. Toxicol Sci 2007; 100 (1): 203-14
83. Nygaard UC, Samuelsen M, Aase A, et al. The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass. Toxicol Sci 2004; 82: 515-24
84. Don Porto CA, Hoet PH, Verschaeve L, et al. Genotoxic effects of carbon black particles, diesel exhaust particles, and urban air particulates and their extracts on a human alveolar epithelial cell line (A549) and a human monocytic cell line (THP-1). Environ Mol Mutagen 2001; 37: 155-63
85. Don Porto CA, Hoet PH, Nemery B, et al. HLA-DR ex- pression after exposure of human monocytic cells to air particulates. Clin Exp Allergy 2002; 32 (2): 296-300
86. Van ZM, Granum B. Adjuvant activity of particulate pollutants in different mouse models. Toxicology 2000; 152 (1-3): 69-77
87. Goodman CM, McCusker CD, Yilmaz T, et al. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 2004; 15 (4): 897-900
88. Bottini M, Bruckner S, Nika K, et al. Multi-walled carbon nanotubes induce T lymphocyte apoptosis. Toxicol Lett 2006; 160 (2): 121-6
89. Fiorito S, Serafino A, Andreola F, et al. Toxicity and biocompatibility of carbon nanoparticles. J Nanosci Nanotechnol 2006; 6 (3): 591-9
90. Chen YW, Hwang KC, Yen CC, et al. Fullerene derivatives protect against oxidative stress in RAW 264.7 cells and ischemia-reperfused lungs. Am J Physiol Regul Integr Comp Physiol 2004; 287 (1): R21-6
91. Barlow PG, Brown DM, Donaldson K, et al. Reduced alveolar macrophage migration induced by acute ambient particle (PM(10)) exposure. Cell Biol Toxicol 2008; 24 (3): 243-52
92. Brown DM, Kinloch IA, Bangert U, et al. An in vitro study of the potential of carbon nanotubes and nanofibres to induce inflammatory mediators and frustrated phagocytosis. Carbon 2007; 45 (9): 1743-56
93. Shaunak S, Thomas S, Gianasi E, et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004; 22 (8): 977-84
94. Cromer JR, Wood SJ, Miller KA, et al. Functionalized dendrimers as endotoxin sponges. Bioorg Med Chem Lett 2005; 15 (5): 1295-8
95. Shvedova AA, Fabisiak JP, Kisin ER, et al. Sequential exposure to carbon nanotubes and bacteria enhances pulmonary inflammation and infectivity. Am J Respir Cell Mol Biol 2008; 38 (5): 579-90
96. Hoek G, Brunekreef B, Fischer P, et al. The association between air pollution and heart failure, arrhythmia, embolism, thrombosis, and other cardiovascular causes of death in a time series study. Epidemiology 2001; 12 (3): 355-7
97. Pope III CA, Verrier RL, Lovett EG, et al. Heart rate variability associated with particulate air pollution. Am Heart J 1999; 138 (5 Pt 1): 890-9
98. Samet JM, Dominici F, Curriero FC, et al. Fine particulate air pollution and mortality in 20 US cities, 1987-1994. N Engl J Med 2000; 343 (24): 1742-9
99. Baccarelli A, Zanobetti A, Martinelli I, et al. Effects of exposure to air pollution on blood coagulation. J Thromb Haemost 2007; 5 (2): 252-60
100. Nemmar A, Hoylaerts MF, Hoet PH, et al. Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol Appl Pharmacol 2003; 186 (1): 38-45
101. Niwa Y, Iwai N. Nanomaterials induce oxidized lowdensity lipoprotein cellular uptake in macrophages and platelet aggregation. Circ J 2007; 71 (3): 437-44
102. Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 2006; 15 (6): 318-30
103. Tran CL, Buchanan D, Cullen RT, et al. Inhalation of poorly soluble particles: II. Influence of particle surface area on inflammation and clearance. Inhal Toxicol 2000; 12 (12): 1113-26
104. EMEA. Reflection paper on nanotechnology-based medicinal products for human use, 29 June 2006 [online]. Available from URL: http://www.emea.europa.eu/ pdfs/ human/genetherapy/7976906en.pdf [Accessed 2009 May 29]
105. D'Silva J, Van Calster G. Taking temperature: a review of European Union regulation in nanomedicine (October 15, 2008) [online]. Available from URL: http://ssrn.com/ abstract=1285099 [Accessed 2009 Jun 03]
106. EMEA. Mandate of the EMEA Innovation Task Force (ITF), 11 April 2006 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/itf/ itfmandate.pdf [Accessed 2009 May 29]
107. FDA. Nanotechnology: a report of the US Food and Drug Administration Nanotechnology Task Force, 25 July 2007 [online]. Available from URL: http://www.fda.gov/ nanotechnology/taskforce/report2007.html
108. Alderson NE. Is special FDA regulation of nanomedicine needed? A conversation with Norris E. Alderson - interview by Barbara J. Culliton. Health Aff (Millwood) 2008; 27 (4): w315-7
109. Gaspar R. Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals. Nanomedicine 2007; 2: 143-7
110. Resnik DB, Tinkle SS. Ethical issues in clinical trials involving nanomedicine. Contemp Clin Trials 2007; 28: 433-41
111. DeVille KA. Law, regulation and the medical use of nanotechnology. In: Jotterand F, editor. Emerging conceptual, ethical and policy issues in bionanotechnology. Philosophy and medicine. Vol. 101. Dordrecht: Springer, 2008: 181-200